Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Grail spins back into Illumina for $8bn
Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.
Panlin picks up $148m fund
Unnamed corporates have provided capital for Panlin’s $148m fund that will focus on healthcare, digital transformation and smart hardware.
K Wah helps Hrain close series B-plus
K Wah Group’s subsidiary has taken part in the tumour therapy and drug developer’s $29.3m round, which came a year after its $28m series B round.
Chasing the light at the end of the tunnel
Global University Venturing: Covid-19 remains a threat but universities are at the forefront of fighting back
Roche fires up $448m Inflazome acquisition
Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Compass navigates IPO
Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.
Finch has the guts for $90m series D
SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.
Kyee accumulates $64m in series D funding
Tencent has led a $64m series D round for the healthtech developer, whose shareholders already include SoftBank.

Other News

Corporate venturing deal net: 14-18 September 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Amwell rams its way to $742m IPO
The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.
Outset Medical pumps IPO up to $278m
The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.
Palleon packs $100m into series B
SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned having already backed the cancer and inflammatory disease drug developer at series A stage.
Olive swallows $106m
The healthcare-focused workplace management software provider hiked its total funding to about $225m as Ascension Ventures reinvested.
Corporates floor Lava with $83m
Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer with backing from returning investor MRL Ventures Fund.

Editor's Picks

Amwell rams its way to $742m IPO
The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.
Grail to pour itself on to public markets
Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.
Kymera climbs to $174m IPO
The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.
Relay receives $400m in initial public offering
The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.
test reg